Sunday, February 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Research publication trends during COVID-19

At first, COVID-19 papers (and preprints) focused on the spread of disease, the outcomes for people hospitalized, and diagnostics and testing, according to an analysis of the topics of PubMed-indexed articles by Primer, a company in San Francisco, California, that develops artificial-intelligence (AI) technologies. But these kinds of paper mostly plateaued after May, and there has been growing interest in mental-health research.

The pandemic also saw a sharp rise in sharing through preprints (articles posted online before peer review), advanced the output of male authors over female authors and affected review times — speeding them up in some topics but slowing them down in others.

More than 30,000 of the COVID-19 articles published in 2020 were preprints — between 17% and 30% of total COVID-19 research papers (depending on database searched). And, according to Dimensions, one-tenth of all preprints this year were about COVID-19.

More than half of the preprints appeared on one of three sites — medRxiv, SSRN and Research Square.

 

Source: Nature

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!